2. Search Result
Search Result
Results for "

AXL kinase inhibitor

" in MedChemExpress (MCE) Product Catalog:

41

Inhibitors & Agonists

1

Fluorescent Dye

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

2

Natural
Products

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-12494
    LDC1267
    5+ Cited Publications

    		 TAM Receptor Inflammation/Immunology Cancer
    LDC1267 is a highly selective TAM (Tyro3, Axl and Mer) kinase inhibitor with IC50s of <5 nM/8 nM/29 nM for Tyro3,Axl and Mer respectively .
    LDC1267
  • HY-12963
    Dubermatinib
    5+ Cited Publications

    TP-0903

    		 TAM Receptor Apoptosis Cancer
    Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC50 value of 27 nM.
    Dubermatinib
  • HY-152830
    Adrixetinib

    Q702

    		 c-Fms TAM Receptor Cancer
    Adrixetinib (Q702) is an Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity .
    Adrixetinib
  • HY-144708
    Axl-IN-4

    		TAM Receptor Cancer
    Axl-IN-4 (Compound 24) is an AXL kinase inhibitor with an IC50 of 28.8 μM .
    Axl-IN-4
  • HY-144706
    Axl-IN-3

    		TAM Receptor Cancer
    Axl-IN-3 is a potent, selective and orally active AXL kinase inhibitor with an IC50 of 41.5 nM. Axl-IN-3 has lower inhibition of other kinases .
    Axl-IN-3
  • HY-N12041
    Axl-IN-16

    		TAM Receptor HIF/HIF Prolyl-Hydroxylase Cancer
    Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .
    Axl-IN-16
  • HY-153012
    Axl/Mer/CSF1R-IN-1

    		TAM Receptor c-Fms Cancer
    Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with Kds of <0.1 μM .
    Axl/Mer/CSF1R-IN-1
  • HY-176204
    Axl-IN-19

    		TAM Receptor Cancer
    Axl-IN-19 (Compound 68) is a selective AXL (a membrane-bound receptor tyrosine kinase) inhibitor (IC50: 5.3 nM; Cellular KD = 6.8 nM). Axl-IN-19 has favorable rat PK with low clearance and moderate bioavailability. Axl-IN-19 can be used for cancer research .
    Axl-IN-19
  • HY-162103
    Axl-IN-18

    		TAM Receptor Apoptosis Cancer
    Axl-IN-18 (compound 25c) is a potent and selective type II AXL inhibitor. Axl-IN-18 shows excellent AXL inhibitory activity (IC50=1.1 nM) and 343-fold selectivity over the highly homologous kinase MET in biochemical assays (IC50=377 nM). Axl-IN-18 significantly inhibits AXL-driven cell proliferation, dose-dependently suppresses 4T1 cell migration and invasion, and induces apoptosis. Axl-IN-18 shows noticeable antitumor efficacy in a BaF3/TEL-AXL xenograft model .
    Axl-IN-18
  • HY-132893
    AZ14145845

    		TAM Receptor Cancer
    AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
    AZ14145845
  • HY-173400
    UNC8212

    		TAM Receptor Cancer
    UNC8212 is a TAM kinase inhibitor. UNC8212 has potent inhibitory activity against MERTK and AXL (IC50: 1.5 nM and 1.3 nM, respectively), and also inhibits TYRO3 (IC50: 6.7 nM). UNC8212 mediates polypharmacological properties by targeting the structurally diverse "back pocket" region of the TAM kinase family. UNC8212 binds tightly to TAM kinases and potently inhibits MERTK and AXL phosphorylation. UNC8212 has anti-tumor effects and can be used in cancer immunotherapy and tumor cell targeting research .
    UNC8212
  • HY-152830A
    Adrixetinib TFA

    Q702 TFA

    		 c-Fms TAM Receptor Cancer
    Adrixetinib (Q702) TFA is a selective Axl/Mer/CSF1R protein tyrosine kinase inhibitor with antineoplastic activity .
    Adrixetinib TFA
  • HY-145622
    Mecbotamab vedotin

    BA3011; CAB-AXL-ADC; CAB-anti-AXL-ADC

    		 TAM Receptor Cancer
    Mecbotamab vedotin (BA301) is an IgG1 antibody inhibitor of anti-(human tyrosine kinase receptor AXL) (human-Mus musculus monoclonal BA301 γ1-chain). Mecbotamab vedotin can be used to make immunoconjugates for Methods of Axl-expressing cancers research .
    Mecbotamab vedotin
  • HY-15797
    UNC2250
    2 Publications Verification

    		 TAM Receptor Cancer
    UNC2250 is a potent and selective Mer inhibitor with an IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.
    UNC2250
  • HY-107145A
    Ningetinib

    		TAM Receptor VEGFR c-Met/HGFR Cancer
    Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
    Ningetinib
  • HY-107145
    Ningetinib Tosylate

    		TAM Receptor VEGFR c-Met/HGFR Cancer
    Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
    Ningetinib Tosylate
  • HY-P99463
    Batiraxcept

    AVB-500; AVB-S6-500

    		 TAM Receptor PI3K Akt p38 MAPK Cancer
    Batiraxcept (AVB-500; AVB-S6-500) is a selective, soluble AXL receptor and GAS6 inhibitor that targets the GAS6-AXL signaling axis. Batiraxcept is orally inactive and does not cross the blood-brain barrier. Batiraxcept competitively binds to GAS6 ((KD <1 nM), preventing its interaction with the AXL receptor tyrosine kinase, thereby inhibiting downstream PI3K/AKT and MAPK signaling pathways, reducing tumor cell glycolysis, angiogenesis, and metastatic potential. Batiraxcept has demonstrated antitumor activity in preclinical models of endometrial, cholangiocarcinoma, and ovarian cancer by inhibiting tumor growth, invasion, and metastasis .
    Batiraxcept
  • HY-15798
    UNC2881

    		VSV TAM Receptor Cardiovascular Disease
    UNC2881 is an orally active and specific Mer kinase inhibitor, inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM. UNC2881 shows additional inhibition against Axl and Tyro with IC50s of 360 nM and 250 nM, respectively. UNC2881 potently inhibits collagen-induced platelet aggregation, can be used for pathologic thrombosis research .
    UNC2881
  • HY-15150
    Bemcentinib
    Maximum Cited Publications
    47 Publications Verification

    R428; BGB324

    		 TAM Receptor Cancer
    Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib
  • HY-147218
    PF-07265807

    		c-Met/HGFR TAM Receptor Cancer
    PF-07265807 is a potent TAM and c-Met kinase inhibitor with IC50 values of 6.1 nM, 13.2 nM and 21.6 nM for AXL, MER and TYRO3, respectively. PF-07265807 can be used for researching anticancer .
    PF-07265807
  • HY-114356
    BPI-9016M

    		c-Met/HGFR Cancer
    BPI-9016M is a potent, orally active, and selective dual c-Met and AXL tyrosine kinases inhibitor. BPI-9016M suppresses tumor cell growth, migration and invasion of lung adenocarcinoma .
    BPI-9016M
  • HY-12044
    Cabozantinib S-malate
    40+ Cited Publications

    XL184 S-malate; BMS-907351 S-malate

    		 VEGFR Apoptosis Cancer
    Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Cabozantinib S-malate
  • HY-12964
    SGI-7079
    3 Publications Verification

    		 TAM Receptor Cancer
    SGI-7079 is a selective, ATP-competitive, orally active inhibitor of the receptor tyrosine kinase Axl. SGI-7079 blocks Axl-mediated signaling pathways such as NF-κB activation and MMP-9 expression, thereby inhibiting tumor cell proliferation, migration and invasion. SGI-7079 is mainly used in the research of malignant tumors such as inflammatory breast cancer and bladder cancer, as well as in combination with immunization (used in combination with PD-1 therapy)[1][2][3].
    SGI-7079
  • HY-13016S1
    Cabozantinib-d4

    XL184-d4; BMS-907351-d4

    		 VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib-d4 is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Cabozantinib-d4
  • HY-116000
    Glumetinib
    1 Publications Verification

    Gumarontinib; SCC244

    		 c-Met/HGFR Cancer
    Glumetinib (SCC244) is a highly selective, orally bioavailable, ATP-competitive c-Met inhibitor with an IC50 of 0.42 nM. Glumetinib has greater than 2400-fold selectivity for c-Met over those 312 kinases evaluated, including the c-Met family member RON and highly homologous kinases Axl, Mer, TyrO3. Antitumor activity .
    Glumetinib
  • HY-147695
    c-Met-IN-12

    		c-Met/HGFR Cancer
    c-Met-IN-12 (compound 4r) is an orally active, potent and selective type II c-Met kinase inhibitor, with an IC50 of 10.6 nM. c-Met-IN-12 displays high inhibitory effects (inhibition rate > 80% in 1 μM) against AXL, Mer and TYRO3 kinases. c-Met-IN-12 can be used a scaffold for further kinase selectivity enhancement. c-Met-IN-12 shows antitumor efficacy .
    c-Met-IN-12
  • HY-138696
    Zanzalintinib
    1 Publications Verification

    XL092

    		 TAM Receptor c-Met/HGFR VEGFR Cancer
    Zanzalintinib (XL092) is an orally active, ATP-competitive inhibitor of multiple receptor tyrosine kinases (RTKs) including MET, VEGFR2, AXL and MER, with IC50s in cell-based assays of 15 nM, 1.6 nM, 3.4 nM, 7.2 nM respectively. Zanzalintinib exhibits anti-tumor activity. Zanzalintinib has the potential for kinase-dependent diseases and conditions research .
    Zanzalintinib
  • HY-13016S
    Cabozantinib-d6

    XL184-d6; BMS-907351-d6

    		 VEGFR c-Met/HGFR c-Kit TAM Receptor FLT3 Apoptosis Cancer
    Cabozantinib-d6 is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively .
    Cabozantinib-d6
  • HY-117548
    UNC1062
    1 Publications Verification

    		 TAM Receptor Cancer
    UNC1062 is a MERTK-selective tyrosine kinase inhibitor, reduces activation of MERTK-mediated downstream signaling, induces apoptosis in culture, reduces colony formation in soft agar, and inhibits invasion of melanoma cells. UNC1062 potently inhibits MERTK kinase activity (MERTK IC50=1.1 nM, Morrison Ki=0.33 nM) and exhibits specificity within the TAM family (TYRO3 IC50=60 nM, AXL IC50=85 nM) .
    UNC1062
  • HY-117596
    UNC569
    1 Publications Verification

    		 TAM Receptor Cancer
    UNC569 is a potent, reversible, ATP-competitive and orally active Mer kinase inhibitor with an IC50 of 2.9 nM and a Ki of 4.3 nM. UNC569 also inhibits Axl and Tyro3 with IC50s of 37 nM and 48 nM, respectively. UNC569 can be used for acute lymphoblastic leukemia (ALL) and atypical teratoid/rhabdoid tumors research
    UNC569
  • HY-125510
    UNC2541
    1 Publications Verification

    		 TAM Receptor Neurological Disease Inflammation/Immunology
    UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor, binds in the MerTK ATP pocket, with an IC50 of 4.4 nM, more selective over Axl, Tyro3 and Flt3. UNC2541 inhibits phosphorylated MerTK (pMerTK; EC50, 510 nM). UNC2541 abolishes the analgesic and anti-inflammatory effects of ozone in vivo and in vitro .
    UNC2541
  • HY-15150G
    Bemcentinib (GMP)

    R428 (GMP); BGB324 (GMP)

    		 TAM Receptor Cancer
    Bemcentinib (R428) GMP is Bemcentinib (HY-15150) in GMP grade. GMP-grade small molecules can be used as auxiliary reagents in cell therapy.Bemcentinib (R428) is a selective and orally active Axl inhibitor with an IC50 of 14 nM. Bemcentinib retards cancer cell migration and invasion. Bemcentinib exhibits >100-fold selectivity for Axl versus Abl and 50- and >100-fold selectivity over TAM family kinases Mer and Tyro3, respectively, in cells. Bemcentinib blocks tumor spread and prolongs survival in models of metastatic breast cancer .
    Bemcentinib (GMP)
  • HY-114357A
    DS-1205b free base

    		TAM Receptor c-Met/HGFR Trk Receptor Cancer
    DS-1205b free base is a potent and selective inhibitor of AXL kinase, with an IC50 of 1.3 nM. DS-1205b free base also inhibits MER, MET, and TRKA, with IC50s of 63, 104, and 407 nM, respectively. DS-1205b free base can inhibit cell migration in vitro and tumor growth in vivo .
    DS-1205b free base
  • HY-100833R
    Antibiotic-5d (Standard)

    		Reference Standards Bacterial Antibiotic Infection
    Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Antibiotic-5d (Standard)
  • HY-12044R
    Cabozantinib (S-malate) (Standard)

    		VEGFR Apoptosis Cancer
    Cabozantinib (S-malate) (Standard) is the analytical standard of Cabozantinib (S-malate). This product is intended for research and analytical applications. Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.
    Cabozantinib (S-malate) (Standard)
  • HY-N3634
    Corylifol C

    		EGFR TAM Receptor Tie Cancer
    Corylifol C is a potent protein kinase inhibitor with IC50 valueS of 8.7, 3.0, 2.1, 6.4, 4.5, 6.2, 2.3, 1.2, 5.1 μg/ml for ARK5, Aurora-A, Aurora-B, AXL, B-RAF-VE, CDK4/CycD1, TIE2, EGF-R, EPHB4, respectively .
    Corylifol C
  • HY-12076
    BMS 777607
    10+ Cited Publications

    BMS 817378

    		 c-Met/HGFR TAM Receptor Cancer
    BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC50s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .
    BMS 777607
  • HY-162645
    BPR5K230

    		TAM Receptor Inflammation/Immunology Cancer
    BPR5K230 is a dual inhibitor for the receptor tyrosine kinase MER and AXL, with IC50 of 4.1 nM and 9.2 nM. BPR5K230 inhibits the proliferation of Ba/F3-MER with IC50 of 5 nM. BPR5K230 exhibits good pharmacokinetic characteristics in mice, exhibits anti-inflammatory and antitumor against 4T1, MDA-MB-231, MC38 and Hepa1?6 in mouse models .
    BPR5K230
  • HY-12965B
    (Z)-S49076 hydrochloride

    		TAM Receptor Cancer
    (Z)-S49076 hydrochloride is an orally active inhibitor of MET and AXL that blocks the downstream signaling of these receptors both in vitro and in vivo, inhibiting the proliferation and migration of tumor cells and suppressing tumor growth in xenograft models. (Z)-S49076 hydrochloride is capable of overcoming the resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) due to MET amplification in Erlotinib (HY-50896)-resistant cell lines both in vitro and in vivo. (Z)-S49076 hydrochloride can be used for research in non-small cell lung cancer (NSCLC) .
    (Z)-S49076 hydrochloride
  • HY-16961
    Sitravatinib
    5 Publications Verification

    MGCD516; MG-516

    		 VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib (MGCD516) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib
  • HY-16961A
    Sitravatinib malate

    MGCD516 malate; MG-516 malate

    		 VEGFR c-Kit FLT3 Discoidin Domain Receptor Trk Receptor Inflammation/Immunology Cancer
    Sitravatinib malate (MGCD516 malate) is an orally bioavailable receptor tyrosine kinase (RTK) inhibitor with IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively . Sitravatinib malate shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment .
    Sitravatinib malate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: